OKYO
Income statement / Annual
Last year (2024), OKYO Pharma Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, OKYO Pharma Limited's net income was -$16,825.46.
See OKYO Pharma Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$7,506.16 |
$3,797.00 |
$2,423.01 |
$13,086.00 |
$5,971.08 |
$219.17 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$7,506.16 |
-$3,797.00 |
-$2,423.01 |
-$13,086.00 |
-$5,971.08 |
-$219.17 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$8,243.57
|
$6.34 M
|
$1.61 M
|
$348,347.00
|
$517,457.00
|
$3.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$573,427.00
|
$363,199.00
|
$1.05 M
|
$1.74 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$0.00
|
$6.75 M
|
$4.93 M
|
$2.97 M
|
$995,422.00
|
$1.85 M
|
$573,427.00
|
$363,199.00
|
$1.05 M
|
$1.74 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$15,811.92 |
-$12,427.12 |
$116,919.00 |
$48,569.00 |
$0.00 |
| Operating Expenses |
$8,243.57 |
$13.19 M |
$6.22 M |
$3.37 M |
$1.51 M |
$4.54 M |
$1.04 M |
$363,269.00 |
$1.10 M |
$1.75 M |
| Cost And Expenses |
$15,749.00 |
$13.19 M |
$6.22 M |
$3.37 M |
$1.52 M |
$4.54 M |
$1.04 M |
$363,269.00 |
$1.10 M |
$1.75 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$48,065.00 |
$0.00 |
$0.00 |
$4,421.82 |
$12,358.00 |
$17,292.00 |
| Interest Expense |
$1.05 M |
$96,687.00 |
$0.00 |
$1,123.00 |
$1,156.88 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.87
|
$3,797.00
|
$2,331.00
|
$13,111.00
|
$5,971.08
|
$217.82
|
$104.61 M
|
$52,516.00
|
-$18,715.00
|
$0.00
|
| EBITDA |
-$15,745.87
|
-$13.18 M
|
-$6.22 M
|
-$3.35 M
|
-$1.51 M
|
-$4.54 M
|
$26.17 M
|
-$363,269.20
|
-$1.12 M
|
-$1.75 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1,053.31
|
-$96,687.00
|
$0.00
|
$754,848.00
|
-$99,494.00
|
-$363,045.52
|
-$12,427.12
|
$121,341.00
|
$96,003.00
|
$0.00
|
| Income Before Tax |
-$16,803.05 |
-$13.28 M |
-$6.22 M |
-$3.38 M |
-$1.62 M |
-$4.90 M |
-$28.27 M |
-$241,927.43 |
-$1.01 M |
-$1.49 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$22.42 |
-$12,202.00 |
-$786,521.00 |
-$24,994.00 |
-$76,194.00 |
-$171,642.18 |
$0.83 |
-$56,937.82 |
-$189,987.78 |
$6.76 M |
| Net Income |
-$16,825.46 |
-$13.27 M |
-$5.43 M |
-$3.35 M |
-$1.54 M |
-$4.90 M |
-$28.27 M |
-$241,927.43 |
-$820,171.01 |
-$8.26 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.0006 |
-0.6 |
-0.0055 |
-0.005 |
-0.0026 |
-0.0095 |
-0.0738 |
-0.0006 |
-0.0022 |
-0.0219 |
| EPS Diluted |
-0.0006 |
-0.6 |
-0.0055 |
-0.005 |
-0.0026 |
-0.0095 |
-0.0738 |
-0.0006 |
-0.0022 |
-0.0219 |
| Weighted Average Shares
Out |
$29.34 M
|
$22.26 M
|
$979.21 M
|
$672.77 M
|
$595.47 M
|
$513.90 M
|
$382.88 M
|
$381.16 M
|
$381.16 M
|
$377.12 M
|
| Weighted Average Shares
Out Diluted |
$29.34 M
|
$22.26 M
|
$979.21 M
|
$672.77 M
|
$595.47 M
|
$513.90 M
|
$382.88 M
|
$381.16 M
|
$381.16 M
|
$377.12 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
